Clearmind Medicine News

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati

BenzingaApr 17 09:13 ET

Express News | Clearmind Medicine Announced An Exclusive Licensing Agreement With Yissum Research Development Company Of The Hebrew University Of Jerusalem For Generation 3.0 Psychedelic Compounds For The Treatment Of Mental Disorders

Moomoo 24/7Apr 17 07:50 ET

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of no

Clearmind MedicineApr 17 00:00 ET

Express News | Clearmind Medicine Announced That It Has Filed A Patent Application With United States Patent And Trademark Office For Psychedelic-based Treatment For Eating Disorders

Moomoo 24/7Apr 10 07:20 ET

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Vancouver, Canada, April 10, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel

Clearmind MedicineApr 10 00:00 ET

Express News | Clearmind Medicine CEO Issues Letter To Shareholders; Says Poised To Achieve Significant Milestones That It Hopes To Substantially Enhance Shareholder Value Through 2024

Moomoo 24/7Apr 9 08:09 ET

Clearmind Medicine CEO Issues Letter to Shareholders

Vancouver, Canada, April 09, 2024 -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE:CWY0) ("Clearmind" or the "company"), a clinical-stage biotech company focused on discovery and development of novel ps

Clearmind MedicineApr 9 00:00 ET

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr

BenzingaMar 30 08:57 ET

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P

BenzingaMar 29 12:43 ET

SciSparc- Clearmind Collaboration Evolves With New International Patent Application for Preventing and Treating Depression

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to

GlobeNewswireMar 27 08:55 ET

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Vancouver, Canada, March 27, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-deri

Clearmind MedicineMar 27 00:00 ET

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More

FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c

BenzingaMar 20 14:49 ET

EURN, STI and PUK Among Pre-market Losers

Seeking AlphaMar 20 08:11 ET

CSE Bulletin: Delist - Clearmind Medicine Inc. (CMND)

Toronto, Ontario--(Newsfile Corp. - Le 13 mars/March 2024) - The common shares of Clearmind Medicine Inc. will be delisted from the CSE at market close, March 14, 2024. The common shares currently tra

newsfileMar 13 14:55 ET

Clearmind Medicine Obtains Clearance For Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. (CMND.CN) has received approval from the Israeli Ministry of Health to begin its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's propriet

MT NewswiresMar 13 08:58 ET

Clearmind Medicine Streamlines NASDAQ Trading

TipRanksMar 13 08:49 ET

Express News | Clearmind Medicine Obtains Israeli Ministry Of Health Clearance To Commence Phase I/IIa Trial For Alcohol Use Dislorder

Moomoo 24/7Mar 13 08:14 ET

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Vancouver, Canada, March 13, 2024 -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of

Clearmind MedicineMar 13 00:00 ET

Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation

Seeking AlphaMar 7 11:29 ET

Rentokil Initial, Avangrid, American Eagle Outfitters Among Premarket Gainers' Pack

Seeking AlphaMar 7 09:09 ET